Aneurysm News and Research

RSS

Endologix 2010 third quarter total revenue increases 30% to $17.9 million

Endologix, Inc. developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2010.

28 Oct 2010

Columbia University researchers to use IBM's streaming analytics to detect complications in brain injury

IBM today announced a new project in which researchers at Columbia University Medical Center will utilize IBM's streaming analytics technology to potentially detect severe complications in brain injured patients up to 48 hours earlier than traditional methods.

27 Oct 2010

PolyMedix plans PMX-60056 Phase 2 clinical trial in interventional cardiology

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).

21 Oct 2010

Annals of Vascular Surgery publishes Endologix's Powerlink System clinical trial results for AAA endovascular repair

Endologix, Inc. developer of minimally invasive treatments for aortic disorders, announced today the publication of results from its pivotal, multicenter, prospective clinical trial of the Company's Powerlink System for endovascular repair of abdominal aortic aneurysm (AAA) using an anatomical fixation technique with a suprarenal aortic extension.

19 Oct 2010

New data on implementation of minimally invasive treatments for ruptured intracranial aneurysms

Two recent studies from the Zeenat Qureshi Stroke Research Center, in Minneapolis, MN, provide new data regarding implementation of minimally invasive treatments for ruptured intracranial aneurysms and impact on patient outcomes in U.S.

11 Oct 2010

Gore commences treatment in Europe with new 25 cm VIABAHN Endoprosthesis

W. L. Gore & Associates announced the treatment of the first European patients with the new 25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, the longest length stent-graft available in Europe. Piotr Kasprzak, from the Department of Vascular Surgery at the Klinikum der Universität in Regensburg, Germany, and Thomas Zeller, MD, from the Department of Angiology at the Herz-Zentrum in Bad Krozingen, Germany successfully treated patients using the Gore device.

23 Sep 2010

Environmental factors are cause of subarachnoid haemorrhage in most cases

The Nordic twin study investigating the heritability of subarachnoid haemorrhage (SAH) suggests that the role of genetic factors underlying the development of SAH is less than previously believed.

20 Sep 2010

GORE C3 Delivery System enables repositioning of stent graft during procedure for AAA

W. L. Gore & Associates (Gore) today announced the first clinical uses of the GORE C3 Delivery System to deploy the GORE EXCLUDER AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA).

16 Sep 2010

Actress joins UTHealth to establish 'John Ritter Research Program in Aortic and Vascular Diseases'

Actress, writer and aortic health advocate Amy Yasbeck has joined with The University of Texas Health Science Center at Houston (UTHealth) to establish the John Ritter Research Program in Aortic and Vascular Diseases (JRRP) to combat the devastating disease that took the life of her husband, legendary comic actor John Ritter.

15 Sep 2010

Long-term stenting of aortic coarctation yields 77% success rate

Researchers from the Congenital Cardiovascular Interventional Study Consortium (CCISC) who evaluated the intermediate and long-term results of stent implantation for aortic coarctation found that cumulative intermediate success was 86%, and cumulative long-term success was 77%. Results of this study appear in the October issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions.

14 Sep 2010

Aptus Endosystems announces completion of $15M Series AA financing

Aptus Endosystems, Inc., a medical device company developing advanced technology for endovascular aneurysm repair, announced the completion of a $15 million Series AA financing. U.S. Venture Partners and Longitude Capital led the round in continuation of their commitment to Aptus' innovative technologies for the treatment of aortic aneurysms.

30 Aug 2010

UT Southwestern University Hospital - St. Paul earns distinction as Primary Stroke Center

The Joint Commission has certified UT Southwestern University Hospital - St. Paul as a Primary Stroke Center, a distinction for hospitals fostering specialized stroke care for patients.

25 Aug 2010

Study suggests elective surgical repair is safe intervention for abdominal aortic aneurysm

Research from the Society for Vascular Surgery in collaboration with the Mount Sinai School of Medicine Department of Health Evidence and Policy in New York City evaluated the data of 3.1 million patients who were at risk for an abdominal aortic aneurysm (AAA).

20 Aug 2010

Natick VNA offers checklist to help patients make informed choice of home health care provider

Home from the hospital already? As stays for hospital patients grow progressively shorter, even for procedures as serious as repairing a brain aneurysm or inserting a pacemaker, patients' need for highly skilled nursing care at home is growing. Indeed, every week, thousands of these patients are referred to home health care services.

17 Aug 2010

Aptus reports successful treatment with EndoStapling System in Europe

Aptus Endosystems Inc., a medical device company developing advanced technology for endovascular aneurysm repair (EVAR), announced that several patients with aortic aneurysm disease have been successfully treated with the Aptus EndoStapling System in Europe. The innovative helical staple technology enables independent endograft fixation, and is designed to approximate suturing in an open surgical anastomosis. The company continues to build on its U.S. clinical experience which includes 176 patients and deployment of more than 900 EndoStaples.

9 Aug 2010

Oral contraceptives, HRT may protect women against formation, rupture of brain aneurysms: Study

Results from a new study suggest that oral contraceptives and hormone replacement therapy may yield additional benefit of protecting against the formation and rupture of brain aneurysms in women. The findings from this first-of-its-kind study by a neurointerventional expert from Rush University Medical Center were presented at the Society of Neurointerventional Surgery 7th annual meeting.

31 Jul 2010

Study shows estrogen stabilization may protect women from brain aneurysms risk

Results from a retrospective, case-control study presented today at the Society of NeuroInterventional Surgery (SNIS) 7th Annual Meeting could have significant implications for women at risk of brain aneurysms as data shows that oral contraceptives (OC) and hormone replacement therapy (HRT) may yield the additional benefit of protecting against the formation and/or rupture of brain aneurysms – balloon-like sacks that form in a weakened artery wall and, upon bursting, can cause severe disability or death.

31 Jul 2010

Boston Scientific announces launch of Neuroform EZ Stent System in U.S. and Europe

Boston Scientific Corporation today announced the U.S. and European launches of the Neuroform EZ(TM) Stent System, its fourth-generation intracranial aneurysm stent system designed for use in conjunction with endovascular coiling to treat wide-necked aneurysms. The Company plans to launch the product immediately in both markets.

29 Jul 2010

Boston Scientific launches Neuroform EZ Stent System

Boston Scientific Corporation today announced the U.S. and European launches of the Neuroform EZ™ Stent System, its fourth-generation intracranial aneurysm stent system designed for use in conjunction with endovascular coiling to treat wide-necked aneurysms. The Company plans to launch the product immediately in both markets.

26 Jul 2010

Endologix second-quarter total revenue increases 19% to $15.7 million

Endologix, Inc., developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and six months ended June 30, 2010.

23 Jul 2010